A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy

Biochemical and Biophysical Research Communications

Volumn 406, Issue 3, 2011, Pages 311-314

  Jiang, Guan ^a,b   Wei, Zhi Ping ^a   Pei, Dong Sheng ^a   Xin, Yong ^a   Liu, Yan Qun ^a   Zheng, Jun Nian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b Center for Disease Control and Prevention of Xuzhou City   (China)

Author keywords

Conditionally replicating adenoviruses; Gene therapy; Glioma; Melanoma; MGMT; TMZ

Indexed keywords

BETA INTERFERON; INTERLEUKIN 24; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; TEMOZOLOMIDE;

ASTROCYTOMA; CELL DEATH; CYTOTOXICITY; DNA REPAIR; ENZYME INACTIVATION; GENE THERAPY; GLIOMA; HUMAN; MELANOMA; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; SHORT SURVEY;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; GENE SILENCING; GENE THERAPY; GLIOMA; HUMANS; MELANOMA; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA;

EID: 79952739967     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.02.042     Document Type: Short Survey

References (46)

1. Annegers J.F., Schoenberg B.S., Okazaki H., Kurland L.T. Epidemiologic study of primary intracranial neoplasms. Arch. Neurol. 1981, 38:217-219.
2. Louis D.N., Holland E.C., Cairncross J.G. Glioma classification: a molecular reappraisal. Am. J. Pathol. 2001, 159:779-786.
3. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
4. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer J. Clin. 2007, 57:43-66.
5. O'Reilly S.M., Newlands E.S., Glaser M.G., Brampton M., Rice-Edwards J.M., Illingworth R.D., Richards P.G., Kennard C., Colquhoun I.R., Lewis P. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur. J. Cancer 1993, 29A:940-942.
6. Bleehen N.M., Newlands E.S., Lee S.M., Thatcher N., Selby P., Calvert A.H., Rustin G.J., Brampton M., Stevens M.F. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol. 1995, 13:910-913.
7. Yung W.K., Prados M.D., Yaya-Tur R., Rosenfeld S.S., Brada M., Friedman H.S., Albright R., Olson J., Chang S.M., O'Neill A.M., Friedman A.H., Bruner J., Yue N., Dugan M., Zaknoen S., Levin V.A. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal brain tumor group. J. Clin. Oncol. 1999, 17:2762-2771.
8. Newlands E.S., Stevens M.F., Wedge S.R., Wheelhouse R.T., Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev. 1997, 23:35-61.
9. Bajetta E., Del Vecchio M., Bernard-Marty C., Vitali M., Buzzoni R., Rixe O., Nova P., Aglione S., Taillibert S., Khayat D. Metastatic melanoma: chemotherapy. Semin. Oncol. 2002, 29:427-445.
10. Li Y., McClay E.F. Systemic chemotherapy for the treatment of metastatic melanoma. Semin. Oncol. 2002, 29:413-426.
11. Plummer E.R., Middleton M.R., Jones C., Olsen A., Hickson I., McHugh P., Margison G.P., McGown G., Thorncroft M., Watson A.J., Boddy A.V., Calvert A.H., Harris A.L., Newell D.R., Curtin N.J. Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin. Cancer Res. 2005, 11:3402-3409.
12. Rosati S.F., Williams R.F., Nunnally L.C., McGee M.C., Sims T.L., Tracey L., Zhou J., Fan M., Ng C.Y., Nathwani A.C., Stewart C.F., Pfeffer L.M., Davidoff A.M. IFN-beta sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating O6-methylguanine DNA methyltransferase expression. Mol. Cancer Ther. 2008, 7:3852-3858.
13. Wedge S.R., Porteous J.K., Newlands E.S. Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Cancer Chemother. Pharmacol. 1997, 40:266-272.
14. Liu X.Y. Targeting gene-virotherapy of cancer and its prosperity. Cell Res. 2006, 16:879-886.
15. Cody J.J., Douglas J.T. Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther. 2009, 16:473-488.
16. Liu L., Gerson S.L. Targeted modulation of MGMT: clinical implications. Clin. Cancer Res. 2006, 12:328-331.
17. Zheng M., Bocangel D., Ramesh R., Ekmekcioglu S., Poindexter N., Grimm E.A., Chada S. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. Mol. Cancer Ther. 2008, 7:3842-3851.
18. Mhaidat N.M., Zhang X.D., Allen J., Avery-Kiejda K.A., Scott R.J., Hersey P. Temozolomide induces senescence but not apoptosis in human melanoma cells. Br. J. Cancer 2007, 97:1225-1233.
19. Naumann S.C., Roos W.P., Jost E., Belohlavek C., Lennerz V., Schmidt C.W., Christmann M., Kaina B. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Br. J. Cancer 2009, 100:322-333.
20. Vannucchi S., Chiantore M.V., Mangino G., Percario Z.A., Affabris E., Fiorucci G., Romeo G. Perspectives in biomolecular therapeutic intervention in cancer: from the early to the new strategies with type I interferons. Curr. Med. Chem. 2007, 14:667-679.
21. Yoshino A., Katayama Y., Yokoyama T., Watanabe T., Ogino A., Ota T., Komine C., Fukushima T., Kusama K. Therapeutic implications of interferon regulatory factor (IRF)-1 and IRF-2 in diffusely infiltrating astrocytomas (DIA): response to interferon (IFN)-beta in glioblastoma cells and prognostic value for DIA. J. Neurooncol. 2005, 74:249-260.
22. Yoshino A., Ogino A., Yachi K., Ohta T., Fukushima T., Watanabe T., Katayama Y., Okamoto Y., Naruse N., Sano E. Effect of IFN-beta on human glioma cell lines with temozolomide resistance. Int. J. Oncol. 2009, 35:139-148.
23. Natsume A., Wakabayashi T., Ishii D., Maruta H., Fujii M., Shimato S., Ito M., Yoshida J. A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. Cancer Chemother. Pharmacol. 2008, 61:653-659.
24. Natsume A., Ishii D., Wakabayashi T., Tsuno T., Hatano H., Mizuno M., Yoshida J. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res. 2005, 65:7573-7579.
25. Fisher P.B., Sarkar D., Lebedeva I.V., Emdad L., Gupta P., Sauane M., Su Z.Z., Grant S., Dent P., Curiel D.T., Senzer N., Nemunaitis J. Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol. Appl. Pharmacol. 2007, 224:300-307.
26. Gupta P., Su Z.Z., Lebedeva I.V., Sarkar D., Sauane M., Emdad L., Bachelor M.A., Grant S., Curiel D.T., Dent P., Fisher P.B. Mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol. Ther. 2006, 111:596-628.
27. Fisher P.B. Is mda-7/IL-24 a " magic bullet" for cancer?. Cancer Res. 2005, 65:10128-10138.
28. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2002, 2:594-604.
29. Marchetti A., Cecchinelli B., D'Angelo M., D'Orazi G., Crescenzi M., Sacchi A., Soddu S. P53 can inhibit cell proliferation through caspase-mediated cleavage of ERK2/MAPK. Cell Death Differ. 2004, 11:596-607.
30. el-Deiry W.S. Regulation of p53 downstream genes. Semin. Cancer Biol. 1998, 8:345-357.
31. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80:293-299.
32. Roos W.P., Batista L.F., Naumann S.C., Wick W., Weller M., Menck C.F., Kaina B. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 2007, 26:186-197.
33. Tentori L., Orlando L., Lacal P.M., Benincasa E., Faraoni I., Bonmassar E., D'Atri S., Graziani G. Inhibition of O6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Mol. Pharmacol. 1997, 52:249-258.
34. Hermisson M., Klumpp A., Wick W., Wischhusen J., Nagel G., Roos W., Kaina B., Weller M. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J. Neurochem. 2006, 96:766-776.
35. Sasai K., Akagi T., Aoyanagi E., Tabu K., Kaneko S., Tanaka S. O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies. Mol. Cancer 2007, 6:36.
36. Harris L.C., Remack J.S., Houghton P.J., Brent T.P. Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene. Cancer Res. 1996, 56:2029-2032.
37. Srivenugopal K.S., Shou J., Mullapudi S.R., Lang F.F., Rao J.S., Ali-Osman F. Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. Clin. Cancer Res. 2001, 7:1398-1409.
38. Bocangel D., Sengupta S., Mitra S., Bhakat K.K. P53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer Res. 2009, 29:3741-3750.
39. Hannon G.J. RNA interference. Nature 2002, 418:244-251.
40. Pei D.S., Di J.H., Chen F.F., Zheng J.N. Oncolytic-adenovirus-expressed RNA interference for cancer therapy. Expert Opin. Biol. Ther. 2010, 10:1331-1341.
41. Kato T., Natsume A., Toda H., Iwamizu H., Sugita T., Hachisu R., Watanabe R., Yuki K., Motomura K., Bankiewicz K., Wakabayashi T. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene Ther. 2010, 17:1363-1371.
42. Kirn D., Martuza R.L., Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat. Med. 2001, 7:781-787.
43. Qian W., Liu J., Tong Y., Yan S., Yang C., Yang M., Liu X. Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. Leukemia 2008, 22:361-369.
44. Alonso M.M., Gomez-Manzano C., Bekele B.N., Yung W.K., Fueyo J. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res. 2007, 67:11499-11504.
45. Zhao L., Gu J., Dong A., Zhang Y., Zhong L., He L., Wang Y., Zhang J., Zhang Z., Huiwang J., Qian Q., Qian C., Liu X. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum. Gene Ther. 2005, 16:845-858.
46. Jiang G., Zheng J.N., Liu Y.Q. Down-regulation of O6-methylguanine-DNA methyl transferase enhances the effect of temozolomide in melanoma cells. Med. Hypotheses 2011, 76:147-148.